查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1959917

粒子治療市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、系統、應用、癌症類型、地區和競爭格局分類，2021-2031年

Particle Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By System, By Application, By Cancer-type, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球粒子束治療市場預計將從 2025 年的 9.9921 億美元成長到 2031 年的 13.6293 億美元，複合年成長率為 5.31%。

這種特殊的體外放射治療利用質子和重離子等帶電粒子，透過在布拉格峰處釋放最大能量，精準地靶向惡性腫瘤。市場成長的主要驅動力是癌症發生率的上升以及臨床上需要最大限度地減少敏感解剖區域的輻射中毒，這使得人們對這種療法的需求超過了傳統的基於光子的療法。此外，越來越多的臨床證據表明，這種療法在兒童和複雜成人病例中具有更優的患者療效，這也進一步推動了此類治療系統的廣泛應用。

市場概覽
預測期 2027-2031
市場規模：2025年 9.9921億美元
市場規模：2031年 1,362,930,000 美元
複合年成長率：2026-2031年 5.31%
成長最快的細分市場 乳癌
最大的市場 北美洲

然而，該領域的發展仍面臨許多障礙，包括設施建設和維護需要大量資金投入，以及保險報銷政策不一致可能導致患者就醫受阻。這些財務障礙往往限制了營運規模，尤其是在注重成本的醫療環境中。儘管有這些障礙，成熟市場的需求依然強勁。例如，根據美國質子治療協會的數據，2024年美國總合18,202名患者接受了質子治療。

市場促進因素

全球癌症和腫瘤疾病發生率的不斷上升凸顯了精準放射治療性介入的迫切性，也是全球粒子束治療市場發展的主要驅動力。隨著惡性腫瘤發生率的上升，醫療機構不得不採用質子治療等先進方法，以最大限度地控制腫瘤，同時最大限度地減少對重要器官的非靶向輻射暴露。對於傳統光子治療長期毒性風險較高的複雜病例，這項要求尤其重要。為了強調這一日益沉重的負擔，國際癌症研究機構（IARC）在其2024年2月發布的全球癌症負擔新聞稿中預測，到2050年，全球新增癌症病例將超過3500萬例，比2022年成長77%。

同時，緊湊型單腔質子治療系統的技術進步降低了醫療機構的投資門檻，並加速了治療的普及。該領域正從大規模多腔設施轉向模組化、節省面積的解決方案。這使得醫院能夠將粒子治療整合到現有基礎設施中，從而降低財務風險。這種向經濟高效技術的轉變已透過商業性成功得到證實。根據Mevion Medical Systems公司2024年9月發布的新聞稿，其緊湊型質子治療解決方案在過去五年中已佔據美國市場60%的佔有率。為了佐證此類擴充性創新技術的重要性，美國癌症協會於2024年1月發布的《2024年癌症事實與數據》報告預測，美國每年新增癌症病例數將首次超過200萬例。

市場挑戰

醫療領域保險報銷政策的不一致嚴重阻礙了全球粒子束治療市場的發展。儘管粒子束治療具有明顯的臨床優勢，但不確定的支付模式常常削弱了這些高成本設施的營運經濟可行性。這是因為私人保險公司和政府支付機構將質子束治療在許多適應症中歸類為實驗性療法，或設定了嚴格的預先核准要求，導致理賠被拒和付款延遲。這種收入預測的困難使得醫療機構難以收回建設設施所需的大量資本投資，從而阻礙了投資者的參與，並抑制了新興市場新中心的建設。

嚴峻的經濟狀況因現有支付結構的下行壓力而進一步惡化。據美國國家質子治療協會稱，美國醫療保險和醫療補助服務中心提案，自2024年起，將5級放射治療程序的報銷率降低1.5%。此類關鍵治療程序報銷率的降低將直接影響現有機構的營運利潤率。因此，這種財務波動將迫使醫療機構限制患者入院人數或暫停擴張計劃，直接限制市場的整體擴充性和可及性。

市場趨勢

超高劑量FLASH粒子療法的出現正在改變市場格局，它能夠在通常不到一秒的時間內實現超高劑量率的輻射輸送。這項技術模式轉移利用了“FLASH效應”，在嚴格控制腫瘤的同時顯著降低對健康組織的毒性，克服了傳統放射治療通訊協定的許多局限性。該領域的研究正在迅速發展，大量資金投入研發，領先的醫療機構正努力將臨床前研究成果轉化為臨床應用。例如，賓州大學醫學院在2024年5月發表的一篇報導《FLASH：邁向超快新型放射療法的一步》中提到，研究人員獲得了美國國立衛生研究院（NIH）1230萬美元的津貼，用於研究質子束FLASH療法的潛力及其保護癌症患者健康組織的能力。

同時，筆射束掃描（PBS）技術的廣泛應用正逐漸成為業界標準，取代被動散射方法，並提升治療的適用性。 PBS技術能夠實現強度調節質子治療（IMPT），使臨床醫生能夠以布拉格峰的精確度逐點「繪製」腫瘤。這對於治療位於重要結構附近的複雜惡性腫瘤至關重要。這項技術優勢在大型商業合約中得到了充分體現，在這些合約中，PBS功能是新建醫療設施的首要條件。例如，根據2024年5月《影像技術新聞》的報道，IBA與耶魯紐黑文醫療中心和哈特福德醫療保健中心簽訂的合約（價值4,000萬至5,000萬美元）明確包含了配備筆射束掃描技術的系統，這便體現了市場趨勢。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球粒子治療市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依類型（質子束療法、重離子束療法）
    • 系統類型（多房間系統、單房間系統）
    • 依應用領域（治療用途、研究用途）
    • 癌症類型（兒童癌症、肺癌、乳癌、其他癌症）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美粒子治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲粒子治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區粒子療法市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲粒子療法市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲粒子療法市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球粒子治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Advanced Oncotherapy plc
  • Danfysik A/S
  • Hitachi, Ltd
  • IBA LLC
  • Mevion Medical Systems, Inc.
  • Optivus Proton Therapy, Inc.
  • ProTom International, Inc.
  • Provision Healthcare Ltd
  • Sumitomo Heavy Industries, Ltd.
  • Varian Medical Systems, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 23229

The Global Particle Therapy Market is projected to expand from USD 999.21 Million in 2025 to USD 1362.93 Million by 2031, reflecting a compound annual growth rate of 5.31%. This specialized form of external beam radiotherapy utilizes charged particles, including protons and heavy ions, to target malignancies with high precision by depositing maximal energy at the Bragg peak. The market is primarily propelled by the rising incidence of cancer and the clinical imperative to minimize radiation toxicity in sensitive anatomical areas, which drives demand for this modality over traditional photon-based treatments. Additionally, the growing body of clinical evidence demonstrating superior patient outcomes in pediatric and complex adult cases continues to support the broader adoption of these therapeutic systems.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 999.21 Million
Market Size 2031USD 1362.93 Million
CAGR 2026-20315.31%
Fastest Growing SegmentBreast Cancer
Largest MarketNorth America

However, the growth of this sector faces significant hurdles due to the high capital investments required for facility construction and maintenance, as well as inconsistent insurance reimbursement policies that can impede patient access. These financial barriers often limit operational scalability, particularly within cost-sensitive healthcare environments. Despite these obstacles, demand remains strong in established markets; for instance, according to the National Association for Proton Therapy, a total of 18,202 patients received proton therapy treatment across the United States in 2024.

Market Driver

The escalating global prevalence of cancer and oncological disorders serves as a fundamental catalyst for the Global Particle Therapy Market, creating an urgent need for precise radiotherapeutic interventions. As malignancy rates climb, healthcare providers are compelled to adopt advanced modalities like proton therapy that maximize tumor control while minimizing off-target radiation to critical organs, a requirement that is particularly acute for complex cases where conventional photon therapy carries high risks of long-term toxicity. Highlighting this increasing burden, the International Agency for Research on Cancer (IARC) predicted in a February 2024 press release regarding the 'Global Cancer Burden' that new cancer cases globally will rise to over 35 million by 2050, representing a 77% increase from 2022 levels.

Concurrently, technological advancements in compact and single-room proton therapy systems are revolutionizing accessibility by lowering capital barriers for medical institutions. The sector is transitioning from massive multi-room facilities toward modular, smaller-footprint solutions that allow hospitals to integrate particle therapy into existing infrastructures with reduced financial risk. This shift toward cost-efficient technology is demonstrated by commercial traction; according to a September 2024 press release by Mevion Medical Systems, their compact proton therapy solutions captured 60% of the announced United States market over the past five years. Underscoring the critical necessity for such scalable innovations, the American Cancer Society's 'Cancer Facts & Figures 2024' report from January 2024 projects that the United States is expected to surpass 2 million new cancer cases in a single year for the first time.

Market Challenge

Inconsistent insurance reimbursement policies within the healthcare sector constitute a substantial barrier hampering the growth of the Global Particle Therapy Market. Although the clinical advantages of particle therapy are evident, the financial viability of operating these high-cost facilities is frequently undermined by uncertain payment models, as private insurers and government payers often categorize proton therapy as experimental for many indications or enforce strict prior authorization requirements that lead to claim denials and payment delays. This unpredictability in revenue generation makes it difficult for medical institutions to recover the massive capital expenditures required for facility construction, thereby discouraging investors and stalling the development of new centers in emerging markets.

This challenging economic landscape is further intensified by downward pressure on established payment structures. According to the National Association for Proton Therapy, in 2024, the Centers for Medicare & Medicaid Services proposed a 1.5% payment rate decrease for codes mapping to Level 5 Radiation Therapy procedures. Such reductions in reimbursement rates for critical treatment codes directly impact the operational margins of existing facilities. Consequently, this financial volatility forces providers to limit patient intake or halt expansion plans, directly restricting the market's overall scalability and accessibility.

Market Trends

The emergence of Ultra-High Dose FLASH Particle Therapy is transforming the market by enabling the delivery of radiation at ultra-high dose rates, typically in less than one second. This technological paradigm shift leverages the "FLASH effect" to significantly reduce toxicity to healthy tissues while maintaining rigorous tumor control, thereby addressing a critical limitation of conventional radiotherapy protocols. Research momentum in this domain is accelerating rapidly as leading medical institutions seek to translate preclinical success into clinical applications, attracting substantial funding for development. Illustrating this commitment to innovation, according to Penn Medicine, May 2024, in the 'FLASH forward to an ultra-fast new form of radiation' article, researchers secured a 12.3 million US dollar NIH grant to study proton FLASH therapy and its potential to spare normal tissue in cancer patients.

Simultaneously, the widespread adoption of Pencil Beam Scanning (PBS) technology is becoming the industry standard, progressively replacing passive scattering methods to enhance treatment conformity. PBS enables Intensity-Modulated Proton Therapy (IMPT), allowing clinicians to "paint" tumors spot-by-spot with Bragg peak accuracy, which is essential for treating complex malignancies near critical structures. This technological dominance is increasingly reflected in major commercial contracts where PBS capabilities are a primary requirement for new facility installations. Evidencing this market preference, according to Imaging Technology News, May 2024, in an article regarding IBA signing a contract with Yale New Haven Health and Hartford HealthCare, a contract valued between 40 and 50 million US dollars was signed for a system specifically equipped with Pencil Beam Scanning technology.

Key Market Players

  • Advanced Oncotherapy plc
  • Danfysik A/S
  • Hitachi, Ltd
  • IBA LLC
  • Mevion Medical Systems, Inc.
  • Optivus Proton Therapy, Inc.
  • ProTom International, Inc.
  • Provision Healthcare Ltd
  • Sumitomo Heavy Industries, Ltd.
  • Varian Medical Systems, Inc.

Report Scope

In this report, the Global Particle Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Particle Therapy Market, By Type

  • Proton therapy
  • Heavy-ion therapy

Particle Therapy Market, By System

  • Multi-room systems
  • Single-room systems

Particle Therapy Market, By Application

  • Treatment application
  • Research application

Particle Therapy Market, By Cancer-type

  • Pediatric Cancer
  • Lung Cancer
  • Breast cancer
  • Other cancers

Particle Therapy Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Particle Therapy Market.

Available Customizations:

Global Particle Therapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Particle Therapy Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Proton therapy, Heavy-ion therapy)
    • 5.2.2. By System (Multi-room systems, Single-room systems)
    • 5.2.3. By Application (Treatment application, Research application)
    • 5.2.4. By Cancer-type (Pediatric Cancer, Lung Cancer, Breast cancer, Other cancers)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America Particle Therapy Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By System
    • 6.2.3. By Application
    • 6.2.4. By Cancer-type
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Particle Therapy Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By System
        • 6.3.1.2.3. By Application
        • 6.3.1.2.4. By Cancer-type
    • 6.3.2. Canada Particle Therapy Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By System
        • 6.3.2.2.3. By Application
        • 6.3.2.2.4. By Cancer-type
    • 6.3.3. Mexico Particle Therapy Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By System
        • 6.3.3.2.3. By Application
        • 6.3.3.2.4. By Cancer-type

7. Europe Particle Therapy Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By System
    • 7.2.3. By Application
    • 7.2.4. By Cancer-type
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Particle Therapy Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By System
        • 7.3.1.2.3. By Application
        • 7.3.1.2.4. By Cancer-type
    • 7.3.2. France Particle Therapy Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By System
        • 7.3.2.2.3. By Application
        • 7.3.2.2.4. By Cancer-type
    • 7.3.3. United Kingdom Particle Therapy Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By System
        • 7.3.3.2.3. By Application
        • 7.3.3.2.4. By Cancer-type
    • 7.3.4. Italy Particle Therapy Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By System
        • 7.3.4.2.3. By Application
        • 7.3.4.2.4. By Cancer-type
    • 7.3.5. Spain Particle Therapy Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By System
        • 7.3.5.2.3. By Application
        • 7.3.5.2.4. By Cancer-type

8. Asia Pacific Particle Therapy Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By System
    • 8.2.3. By Application
    • 8.2.4. By Cancer-type
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Particle Therapy Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By System
        • 8.3.1.2.3. By Application
        • 8.3.1.2.4. By Cancer-type
    • 8.3.2. India Particle Therapy Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By System
        • 8.3.2.2.3. By Application
        • 8.3.2.2.4. By Cancer-type
    • 8.3.3. Japan Particle Therapy Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By System
        • 8.3.3.2.3. By Application
        • 8.3.3.2.4. By Cancer-type
    • 8.3.4. South Korea Particle Therapy Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By System
        • 8.3.4.2.3. By Application
        • 8.3.4.2.4. By Cancer-type
    • 8.3.5. Australia Particle Therapy Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By System
        • 8.3.5.2.3. By Application
        • 8.3.5.2.4. By Cancer-type

9. Middle East & Africa Particle Therapy Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By System
    • 9.2.3. By Application
    • 9.2.4. By Cancer-type
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Particle Therapy Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By System
        • 9.3.1.2.3. By Application
        • 9.3.1.2.4. By Cancer-type
    • 9.3.2. UAE Particle Therapy Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By System
        • 9.3.2.2.3. By Application
        • 9.3.2.2.4. By Cancer-type
    • 9.3.3. South Africa Particle Therapy Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By System
        • 9.3.3.2.3. By Application
        • 9.3.3.2.4. By Cancer-type

10. South America Particle Therapy Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By System
    • 10.2.3. By Application
    • 10.2.4. By Cancer-type
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Particle Therapy Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By System
        • 10.3.1.2.3. By Application
        • 10.3.1.2.4. By Cancer-type
    • 10.3.2. Colombia Particle Therapy Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By System
        • 10.3.2.2.3. By Application
        • 10.3.2.2.4. By Cancer-type
    • 10.3.3. Argentina Particle Therapy Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By System
        • 10.3.3.2.3. By Application
        • 10.3.3.2.4. By Cancer-type

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Particle Therapy Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Advanced Oncotherapy plc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Danfysik A/S
  • 15.3. Hitachi, Ltd
  • 15.4. IBA LLC
  • 15.5. Mevion Medical Systems, Inc.
  • 15.6. Optivus Proton Therapy, Inc.
  • 15.7. ProTom International, Inc.
  • 15.8. Provision Healthcare Ltd
  • 15.9. Sumitomo Heavy Industries, Ltd.
  • 15.10. Varian Medical Systems, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer